GlassScriptPhysician profile
Howard Noble Greene
NPI 1891726766
$8,209.24
in general payments reported to CMS, 2019-2025
29 companies · $1,156 in 2025
The $1,156 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $657 · 2021: $1,189 · 2022: $1,513 · 2023: $1,465 · 2024: $1,028 · 2025: $1,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,648.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,048.16 | 2019-2025 | Clareon, Rocklatan, Lensx |
| Sight Sciences, INC. | $964.36 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $855.09 | 2019-2022 | |
| Abbvie INC. | $572.40 | 2022-2025 | |
| Rxsight INC | $372.52 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Ocular Therapeutix, INC. | $326.69 | 2022-2025 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $321.12 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $311.05 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $238.87 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $217.41 | 2023-2025 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Mallinckrodt Hospital Products INC. | $208.54 | 2022-2023 | Acthar |
| Bausch & Lomb Americas INC. | $206.50 | 2022-2025 | Vyzulta, Miebo |
| Novartis Pharmaceuticals Corporation | $168.91 | 2019-2022 | |
| Glaukos Corporation | $151.76 | 2020-2024 | Idose |
| Carl Zeiss Meditec USA, INC. | $146.77 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $143.96 | 2022 | |
| Eyepoint US, INC. | $137.52 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $123.69 | 2021 | |
| Oyster Point Pharma, INC. | $112.38 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Horizon Therapeutics Plc | $112.02 | 2021-2023 | Tepezza |
| Omeros Corporation | $98.47 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $96.63 | 2019-2021 | |
| Amgen INC. | $74.66 | 2024 | Tepezza |
| Ivantis, INC | $69.30 | 2020-2021 | |
| Glaxosmithkline, LLC. | $39.54 | 2022 | |
| Akorn, INC. | $39.34 | 2020 | |
| Shire North American Group INC | $35.70 | 2019 | |
| Eyevance Pharmaceuticals LLC | $15.88 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.